Virginia Cancer Specialists Practice Blog

January 30, 2018

Presented by Johns Hopkins University School of Medicine Department of Oncology and Virginia Cancer Specialists

Date & Location
Saturday, March 10, 2018 7:00 AM – 5:00 PM

The Ritz-Carlton, Tysons Corner, McLean, VA

Who Should Attend:

This activity is intended for pulmonologists, thoracic surgeons, oncologists and radiation oncologists.


After attending this activity, the participant will demonstrate the ability to:

  • Identify the appropriate patients for multidisciplinary lung cancer care.
  • Evaluate patients for the appropriate treatments (targeted, immunotherapy) where applicable.
  • Formulate a plan for comprehensive management when multiple therapies are available.
  • Management of toxicities of therapy that may require input from multiple specialties.
Download Brochure Here

Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Credits

  1. American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
  2. American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
  3. American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA
    PRA Category 1 Credit™ from organizations accredited by ACCME.
  4. Physician assistants may receive a maximum of 7.75 AAPA Category 1 CME credit(s) for completing this program.

The Johns Hopkins University has approved this activity for 7.75 contact hours for non-physicians.


The number of new lung cancer therapies for Non Small Cell Lung Cancer (NSCLC) have exploded over the past few years – so has the complexity of treatment, and the need to co-manage patients with a multidisciplinary approach. Oncologists who have traditionally worked independently, are now encouraged to collaborate with colleagues to ensure that the right procedures are followed and appropriate tissue is obtained for the correct treatment plan. It is our goal of this CME activity to bring together the community of medical professionals that co-manage these patients to optimize patient outcomes. Participants will gain insight into novel techniques for the staging of lung cancer,new surgical treatments, controversies in disease, immunotherapy advancements and the management of targeted therapies.

Registration Fee

$165 for physicians

$125 for nurses, fellow, residents and other allied health professionals.

Topics to be Discussed:

  • Novel Techniques for Staging of Lung Cancer (Interventional Pulmonology)  / Dr. Bobby Mahajan
  • Surgical Treatments of Lung Cancer / Dr. Stephen Broderick
  • Thoracic Early Recovery with Ambulation After Surgery (T-ERAS) / Dr. Sandeep Khandhar
  • Novel Approaches Towards Radiation  / Dr. Russell Hales
  • Panel Discussion: Controversies of Stage III Disease  / Drs. Alexander Spira, Russell Hales, Stephen V. Liu, Bobby Mahajan, and Timothy A. McCarthy
  • Biology of Immunotherapy Response and Toxicity / Dr. Stephen Liu
  • Targeted Therapies  / Dr. Alexander Spira
  • Current and Future Status of Immunotherapy in Lung Cancer  / Dr. David Ettinger


Click either link below to register online (Johns Hopkins CME Website)
  1. Register Here

  • Register by Phone (410) 502-9634
  • Register by Fax (866) 510-7088
  • Confirmation/Certificates/Transcripts (410) 502-9634
  • General Information (410) 955-2959

E-mail the Office of CME
Follow us on Twitter:

Related Posts

Investigational Inhibitor of Active RAS Shows Clinical Promise - Alexander I. Spira, MD, PhD, FACP

Clinical Trials Search, Alex Spira MD PhD FACP, Clinical Trials and Research
October 16, 2023
Read More

Landmark Non-Small Cell Lung Cancer Study - Clinically Meaningful Improvement and Progression Free Survival, Alexander I. Spira, MD, PhD, FACP 

Lung Cancer Team, The Research Institute, Alex Spira MD PhD FACP, Clinical Trials and Research, Lung Cancer, Non-Small Cell Lung Cancer
September 28, 2023
Read More

A Rare Breakthrough in the Treatment of Colorectal Cancer Patients Harboring a KRAS mutation.

Alex Spira MD PhD FACP, Colon & Rectal Cancer, Clinical Trials and Research
March 7, 2023
Read More

NEXT-Virginia Opens Phase I Clinical Research Clinic for Oncology Patients in collaboration with Virginia Cancer Specialists

NEXT Oncology, The Research Institute, Alex Spira MD PhD FACP, Clinical Trials and Research, Press Releases
January 10, 2023
Read More

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C - Co-Author Alexandar Spira, MD, PhD, FACP

Alex Spira MD PhD FACP, Colon & Rectal Cancer
January 9, 2023
Read More

Advancements in Lung Cancer Treatment Provide Hope for Virginia Cancer Specialists Patients - Alexander I. Spira, MD, PhD, FACP

Lung Cancer Team, Alex Spira MD PhD FACP, Lung Cancer
November 10, 2022
Read More